The Centre hospitalier universitaire vaudois (CHUV), one of Switzerland’s most prestigious medical institutions, is moving forward with a significant restructuring of its oncology and cellular therapy research divisions. The reorganization will result in the elimination of 50 positions, a move driven by the shifting landscape of research funding and the natural evolution of scientific programs.
The decision marks a difficult transition for the staff involved, but the Vaud Council of State (Conseil d’État) has now finalized the modalities of a comprehensive social plan designed to mitigate the impact. This plan, developed after extensive negotiations with personnel representatives, aims to provide a bridge for affected employees as they navigate the loss of their roles in a highly specialized field.
At the heart of the cuts is a pragmatic, if painful, reality of academic medicine: research positions are often tied to specific grants and funding cycles. When these programs conclude or pivot in direction, the positions associated with them may no longer be financially sustainable. According to the authorities, these 50 roles are no longer funded in the long term, necessitating a reorganization of the department’s activities to align with current scientific priorities and available resources.
A Structured Safety Net for Affected Staff
The social plan adopted by the Council of State goes beyond the standard requirements of the Law on State Personnel (LPers), reflecting the specialized nature of the workforce and the institutional desire to retain talent within the public sector. The strategy focuses on three primary pillars: active redeployment, financial support for retraining, and severance payments based on seniority.
A critical component of the package is the allocation of a training credit of up to 8,000 Swiss francs. This fund is available to all affected individuals, regardless of whether they are transferred internally to another department at CHUV, move to another branch of the Vaud state administration, or seek employment in the private sector. This acknowledges that the skills required for high-level oncology research may need updating or pivoting to fit new roles.
the state has introduced a mobility credit to cover travel expenses associated with securing new employment, ensuring that financial barriers do not hinder the redeployment process. These measures are intended to treat the transition not merely as a termination of employment, but as a professional pivot.
The Path to the Final Agreement
The finalization of this plan was not immediate. It was the result of a rigorous consultative process involving 16 separate discussion sessions with staff representatives. To ensure the gravity of the situation was recognized at the highest level, five of these meetings were attended by members of the Council of State.
An initial draft of the social plan was presented to employees during a general assembly on April 22. Following that meeting, the Council of State reviewed the feedback and demands submitted by the staff, leading to several adjustments before the final version was formally adopted. This iterative process was designed to ensure that the needs of the researchers and support staff were balanced against the budgetary constraints of the hospital.
The human resources teams at CHUV have already begun implementing individualized support plans. To date, 16 of the 50 affected employees have already secured new positions, some within the hospital itself and others within various cantonal institutions.
| Support Measure | Detail/Benefit | Eligibility |
|---|---|---|
| Training Credit | Up to 8,000 CHF | All affected staff |
| Mobility Credit | Travel expense coverage | Staff seeking new roles |
| Redeployment | Active search in CHUV/State of Vaud | All affected staff |
| Severance Pay | Based on years of service | Staff leaving the institution |
The Broader Impact on Oncology Research
While the focus remains on the personnel, the reorganization signals a strategic shift in how CHUV approaches oncology and cellular therapies. By streamlining positions that are no longer funded, the institution aims to reallocate its focus toward emerging research avenues that have secured sustainable backing. This is a common trend in European university hospitals, where the “funding cliff”—the end of a multi-year grant—often forces a recalibration of staff levels.
The challenge for CHUV lies in maintaining its status as a global leader in cancer treatment while managing the volatility of research funding. The loss of 50 positions is a significant blow to the department’s headcount, but the administration maintains that the reorganization is necessary to ensure the long-term viability of the remaining research programs.
For those who have not yet found a new role, the individualized accompaniment provided by HR will continue through the end of the calendar year. This window provides a final push for internal placement before the social plan’s primary support phase concludes.
Disclaimer: This article is provided for informational purposes regarding employment and institutional reorganization and does not constitute legal or professional career advice.
The next critical milestone for the affected staff will be the end-of-year deadline, at which point the current cycle of individualized accompaniment will conclude. Official updates regarding the reorganization’s impact on research output are expected in the hospital’s upcoming annual reporting.
We invite readers to share their thoughts on the balance between research funding and job security in the comments below.
